
• Reported GAAP EPS of -$0.08 down -60.00% YoY • Reported revenue of $211.2M down -4.43% YoY • Neogen is increasing its fiscal year 2026 revenue guidance to $857M to $860M, while maintaining its adjusted EBITDA guidance at approximately $175M for the fiscal year.
Bullish
Neogen will divest its Genomics business for $160M to reduce debt, advanced its Petrifilm manufacturing transition, and expanded Adjusted EBITDA margin to 22.8% due to cost savings.
Bearish
Neogen's Q3 FY26 revenue decreased 4.4% to $211.2M, impacted by a 20.1% decline in Animal Safety due to supplier issues and gross margin compression to 46.9% from Petrifilm transition costs.